Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
6811806 | Psychiatry Research | 2018 | 20 Pages |
Abstract
Omega-3 fatty acid (FA) supplementation has been reported to improve several cardio-metabolic risk factors. We aimed to assess the efficacy of omega-3 fatty acids on metabolic and inflammatory indices in patients with schizophrenia who were taking clozapine and sodium valproate. All patients were on a stable dose of 300-400Â mg of clozapine for 3 months. Subjects were randomized to treatment with either omega-3 fatty acid (4Â gr/day) or a placebo for 8 weeks. Height, weight, abdominal circumference, serum lipid profile, fasting blood glucose (FBG), and serum high sensitivity-C-reactive protein (hs-CRP) were determined at baseline and after 8 weeks of treatment. Fifty six subjects were recruited into the study. Patients with schizophrenia who were in the group receiving omega-3 FA capsules had an improvement in some anthropometric indices including weight, BMI, wrist and waist circumference, compared to the placebo group. Only changes in waist circumferences remained significantly different after adjustment for serum fasted TG. Our results showed omega-3 FA supplementation can improve some anthropometric indices in patients with schizophrenia who are taking clozapine pharmacotherapy.
Keywords
Related Topics
Life Sciences
Neuroscience
Biological Psychiatry
Authors
Fatemeh Behdani, Seyede Narjes Roudbaraki, Maryam Saberi-Karimian, Maryam Tayefi, Paria Hebrani, Amir Akhavanrezayat, Sadegh Vahabi Amlashi, Gordon A. Ferns, Majid Ghayour-Mobarhan,